The Food and Drug Administration has greenlighted Glenmark Pharmaceuticals' generic Micardis (telmisartan and hydrochlorothiazide tablets). Glenmark’s product is the generic of Boehringer Ingelheim Pharmaceuticals’ Micardis HCT tablets.
The product is indicated for the treatment of hypertension, to lower blood pressure. Glenmark's generic will be available in 40 mg telmisartan/12.5 mg hydrochlorothiazide, 80 mg telmisartan/12.5 mg hydrochlorothiazide, and 80 mg telmisartan/25 mg hydrochlorothiazide dosage strengths.
Micardis HCT tablets had a market value of about $40.6 million for the 12 month ended January 2019, according to IQVIA data.